Antithrombotic Activity of a Novel Diazepino[1,2-α] Benzimidazole Derivative on Arterial Thrombosis Model in Rats without Concomitant Pathology and in Rats with Experimental Myocardial Infarction

Antithrombotic activity of a novel tricyclic derivative of diazepino[1,2-α]benzimidazole (DAB-15) was examined on the model of arterial thrombosis developed in rats without concomitant pathology and in rats with experimental myocardial infarction. DAB-15 demonstrated high antithrombotic efficacy in...

Full description

Saved in:
Bibliographic Details
Published in:Bulletin of experimental biology and medicine 2019-04, Vol.166 (6), p.747-750
Main Authors: Spasov, A. A., Kucheryavenko, A. F., Sirotenko, V. S., Anisimova, V. A., Divaeva, L. N., Kuz’menko, T. A., Morkovnik, A. S.
Format: Article
Language:English
Subjects:
Acetylsalicylic acid
Aspirin
Benzimidazoles
Biomedical and Life Sciences
Biomedicine
Carotid artery
Cell Biology
Clopidogrel
Heart attack
Heart attacks
Internal Medicine
Laboratory Medicine
Myocardial infarction
Novels
Pathology
Salicylates
Thrombosis
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Antithrombotic activity of a novel tricyclic derivative of diazepino[1,2-α]benzimidazole (DAB-15) was examined on the model of arterial thrombosis developed in rats without concomitant pathology and in rats with experimental myocardial infarction. DAB-15 demonstrated high antithrombotic efficacy in modeled thrombosis of carotid artery in rats without the concomitant pathology surpassing that of the reference drugs acetylsalicylic acid and clopidogrel by 5.1 and 4.8 times, respectively. In rats with experimental noncoronary myocardial infarction, DAB-15 increased the thrombus formation time by 86.2% in comparison with experimental control level in non-treated rats with similar myocardial infarction.
ISSN:0007-4888
1573-8221
DOI:10.1007/s10517-019-04432-0